Last $13.00 USD
Change Today +0.53 / 4.25%
Volume 74.5K
CNCE On Other Exchanges
As of 1:46 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

concert pharmaceuticals inc (CNCE) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/13/14 - $16.26
52 Week Low
05/21/14 - $7.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

concert pharmaceuticals inc (CNCE) Related Businessweek News

No Related Businessweek News Found

concert pharmaceuticals inc (CNCE) Details

Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation, and cancer. The company’s clinical-stage product candidates include CTP-354, which in Phase I clinical trial for spasticity associated with multiple sclerosis and spinal cord injury; CTP-499 that is in Phase II clinical trial for diabetic kidney disease; and AVP-786 for neurologic and psychiatric disorders. Its preclinical compounds comprise CTP-730 for inflammatory diseases; JZP-386, a deuterated analog of sodium oxybate for narcolepsy; and C-10068, an oral deuterium-substituted analog of dextroethorphan, which is used for the treatment of pain and seizure-generating diseases and injuries, such as epilepsy, ischemic stroke, and traumatic brain injury. The company has collaborations with Avanir Pharmaceuticals, Inc., Celgene Corporation, Celgene International Sàrl, and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

45 Employees
Last Reported Date: 03/31/14
Founded in 2006

concert pharmaceuticals inc (CNCE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $373.2K
Chief Operating Officer
Total Annual Compensation: $300.1K
Senior Vice President and General Counsel
Total Annual Compensation: $295.4K
Compensation as of Fiscal Year 2013.

concert pharmaceuticals inc (CNCE) Key Developments

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) added to NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. will be added to the NASDAQ Biotechnology Index.

Concert Pharmaceuticals Appoints Thomas G. Auchincloss to the Board of Directors and Independent Chair of the Audit Committee

Concert Pharmaceuticals, Inc. announced that Thomas G. Auchincloss, Jr. will join it's board of directors and serve as the independent chair of the board and audit committee, effective immediately. Auchincloss replaces Helmut Schühsler as chair of the audit committee. Dr. Schühsler will remain a member of Concert's board of directors. Auchincloss is a financial expert and seasoned corporate financial executive. He has more than thirty years of financial experience including more than twenty years biotechnology experience in executive level financial, operational and advisory roles. Auchincloss is the former chief financial officer of Metabolix, Inc. Before joining Metabolix, he held a variety of positions at Vertex Pharmaceuticals, Inc. most recently as vice president, finance and treasurer. Auchincloss is presently the managing partner of Counterpoint Trading Company LLC. He also serves as a trustee and treasurer of Kieve Wavus Education, Inc. and as an advisor to Capital Formation Group, Inc. and Acelium.

Concert Pharmaceuticals, Inc. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Concert Pharmaceuticals, Inc. reported consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $4,418,000 compared to $681,000 a year ago. Loss from operations was $7,608,000 compared to $7,116,000 a year ago. Net loss applicable to common stockholders was $7,832,000 or $0.43 per basic and diluted share compared to $7,227,000 or $5.59 per basic and diluted share a year ago. The increase in revenue was primarily due to a $2.0 million development milestone earned under collaboration agreement with Avanir in August 2014 as well as a $1.2 million increase in revenue for services performed under Jazz Pharmaceuticals collaboration agreement. For the six months, the company reported total revenue of $7,266,000 compared to $23,995,000 a year ago. Loss from operations was $21,853,000 compared to income from operations of $1,169,000 a year ago. Net loss applicable to common stockholders was $22,827,000 or $1.52 per basic and diluted share compared to $437,000 or $0.34 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNCE:US $13.00 USD +0.53

CNCE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CNCE.
View Industry Companies

Industry Analysis


Industry Average

Valuation CNCE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONCERT PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at